Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine protects at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”

The pregnancy vaccine functions by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is given four weeks or more before delivery. Even briefer gaps between vaccination and birth can still deliver substantial defence, with evidence suggesting that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if given later in the third trimester.

• Nearly 85 per cent coverage when vaccinated 4 weeks before birth
• Maternal antibodies passed through the placenta safeguard newborns from day one
• Coverage possible with 2-week gap before premature birth
• Vaccination in the third trimester still offers meaningful protection for infants

Strong evidence from the latest research

The effectiveness of the RSV vaccine administered during pregnancy has been confirmed through a comprehensive study conducted across England, examining data from close to 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that six-month timeframe, providing strong and reliable evidence of the vaccine’s real-world impact. The study’s conclusions have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scale of this research provides healthcare professionals and prospective parents with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.

The results paint a notable picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV during the study period, with the overwhelming majority being infants whose mothers had not been given the vaccination. This stark contrast emphasises the vaccine’s vital importance in reducing the risk of serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.

Study design and parameters

The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospital admissions. The large sample size and thorough nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than individual cases or limited subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology assessed practical outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine performs when administered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.

Grasping RSV and the risks

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during busier periods.

The infection triggers deep inflammation in the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed properly. Parents frequently observe their babies visibly struggling, their chests heaving as they work to get enough air into their weakened respiratory system. Whilst most newborns get better with clinical support, a limited though important number die from RSV complications yearly, making prevention through vaccination a vital health service imperative for defending the youngest and most at-risk individuals in the population.

• RSV triggers inflammation in lungs, causing serious respiratory problems in babies
• Half of all newborns acquire the virus in their first few months of life
• Symptoms vary between mild colds to life-threatening chest infections requiring hospitalisation
• Over 20,000 UK babies need serious hospital treatment for RSV annually
• Few infants die from RSV complications annually in the UK

Take-up rates and expert recommendations

Since the RSV vaccine programme launched in 2024, health officials have emphasised the significance of pregnant women receiving their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing is crucial for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery provides nearly 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies through the placenta.

The guidance from public health bodies remains clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.

Regional disparities in vaccination

Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Certain regions have achieved higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to increase awareness and availability of the jab. These geographical variations reflect differences across medical facilities, engagement approaches, and local engagement efforts, though the overall statistics shows consistently strong protection regardless of geographical location.

• NHS trusts deploying multiple messaging strategies to engage with pregnant women
• Regional disparities in vaccine uptake rates throughout England demand focused enhancement
• Community health services adapting programmes to meet local requirements and situations

Real-world impact and parent viewpoints

The vaccine’s remarkable effectiveness provides concrete gains for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the rollout of this preventative solution, the 80% drop in admissions equates to thousands of infants spared from serious illness. Parents no longer face the distressing scenario of watching their newborns labour to breathe or struggle to eat, symptoms that mark critical RSV illness. The vaccine has substantially transformed the landscape of neonatal lung health, giving expectant mothers a preventative option to protect their most vulnerable children during those vital initial period.

For families like that of Malachi, whose serious RSV infection resulted in severe brain damage, the vaccine’s introduction carries deep personal significance. His mother’s support of the jab underscores the life-altering consequences that treatable infection can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to women in pregnancy in their late pregnancy, converting what was once an inevitable seasonal threat into a manageable risk.